Bal Pharma: Enclosed unaudited standalone and consolidated Financial Result of Second quarter 30th September 2026 along…
Bal Pharma (BALPHARMA) filed a disclosure titled "Enclosed unaudited standalone and consolidated Financial Result of Second quarter 30th September 2026 along with Limited Review Report". The company is valued at about ₹134 crore.
What happened
Bal Pharma (BALPHARMA) filed a disclosure with the exchanges on 11 November 2026 at 06:11 PM titled "Enclosed unaudited standalone and consolidated Financial Result of Second quarter 30th September 2026 along with Limited Review Report".
Company snapshot
Bal Pharma is a micro-cap company, with a market value of about ₹134 crore.
The stock last traded at ₹83.91, against a 52-week range of ₹60–₹124.6 (32.7% below the high).
Before this filing the shares had moved −13.5% over the month and −6.8% over three months. Average daily turnover over the last 20 sessions was about ₹0.09 crore.
Promoters held 50.86% at the end of Q1 FY27. Foreign institutions owned 0.15% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 66 | 0.2 | 0.13 |
| Q2 FY26 | 74 | 0.7 | 0.45 |
| Q3 FY26 | 88 | 1.8 | 1.12 |
| Q4 FY26 | 84 | 3.6 | 2.26 |
| Q1 FY27 | 89 | 1.1 | 0.71 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 5.2% on average the next trading day and was down 7.0% on average after five days (2 filings with price data).
Market-wide, 11,585 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 12 Aug 2026 | Outcome of Board Meeting held on August 12, 2026.1 | −3.8% | −4.2% |
| 27 May 2026 | Audited Financial Results-Standalone & Consolidated | −6.5% | −9.7% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 11 November 2026: Board meeting — Financial Results/Other business matters.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.